Over the past 3.5 years the LakePharma Discovery Immunology team has discovered antibodies against 100+ targets with an overall success rate of 97%. We have cryopreserved 10,000+ confirmed lead hybridomas and have obtained sequences for 700+ monoclonal antibodies. Nearly all of the mAbs we discover for a given campaign have unique heavy chain and/or light chain V or J gene usage and/or CDR3 sequences, indicating that our workflow has a strong capacity to deliver mAb diversity. We have worked with 40+ clients on a diverse array of challenging targets from heptahelical transmembrane receptors to small molecules, and >35% of our clients have returned to pursue additional discovery campaigns. We also have extensive experience using mutiple platforms of human antibody-producing transgenic animals.
We enjoy working collaboratively with our clients on challenging projects. Examples include our hybridoma-based antibody discovery to support chimeric antigen receptor (CAR) T development with the Tri-Institutional Therapeutic Discovery Institute (View our poster presented at Antibody Engineering and Therapeutics (AET) conference Dec 2019 below).
Another example is our antibody discovery work with Trianni to discover novel B and T Lymphocyte Antigen (BTLA)-specific therapeutic antibodies for checkpoint inhibition in cancer (webinar presented Spring 2019).
The Discovery Immunology (DI) business unit has served 45 Companies so far.
38% of our clients have returned to pursue additional DI Ab campaigns. 36% of our clients perform multiple campaigns in parallel.
We have completed 97 discovery campaigns through the hit identification stage.
We have successfully identified, confirmed, and cryopreserved multiple hits (non-clonal hybridomas) for 97% of our campaigns.
We have successfully single-cell cloned multiple hybridomas and determined unique mAb sequences for 55+ campaigns.
- Successful in raising mAbs against a many target types, including targets playing a role in ImmunoOncology, Neurology, and Inflammation
- 39% Type I Transmembrane Protein Targets and 8% Type II Transmembrane Proteins
- 17% Multi-pass Transmembrane Protein Targets with success against at least 10 GPCR targets.
- 4% are GPI-linked Membrane Proteins
- 22% are enzymes, plasma proteins, intracellular proteins, and small molecules
Rodent Types Used for Campaigns
For hybridoma discovery and immune phage library generation, we have immunized various human antibody-producing transgenic mice, wild-type mice and rats.